Literature DB >> 1827074

Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.

A Porcile1, E Gallardo.   

Abstract

OBJECTIVE: Effectiveness of 2-year treatment of hirsutism with low estrogen oral contraceptives (OCs) containing nonandrogenic or antiandrogenic progestogen. Evaluation of changes in plasma lipids.
DESIGN: Ten patients treated with desogestrel 150 micrograms + 30 micrograms ethinyl estradiol, 6 with desogestrel 150 micrograms + 50 micrograms ethinyl estradiol, 10 with cyproterone acetate 2 mg + 35 micrograms ethinyl estradiol. Random allocation. Paired comparisons. CONTROL GROUP: 19 normal women, not treated.
SETTING: Academic tertiary care. PATIENTS: Women with hirsutism (idiopathic and/or polycystic ovary), 24 of 26 completed treatment. INTERVENTION: Two-year treatment. MAIN OUTCOME MEASURES: Hirsutism score, plasma testosterone, and lipids.
RESULTS: Initial hirsutism scores (11.8 +/- 0.6 SE) declined with treatment (-7.2 +/- 0.4, P less than 0.01) to 4.7 +/- 0.6, almost reaching control (3.6 +/- 0.3). Initial plasma cholesterol (4.33 mmol/L +/- 0.30 SE), similar to control (4.78 +/- 0.24), increased slowly over 2 years (+2.04 +/- 0.34, P less than 0.01). High-density lipoproteins cholesterol (1.05 mmol/L +/- 0.04 SE), similar to control (1.12 +/- 0.07), did not change the 1st year and increased at 2 years (+0.57 +/- 0.11, P less than 0.01). No differences appeared among treatment groups.
CONCLUSIONS: Treatment is very effective, 2 years for best results. The OCs tested are equally efficacious. Changes in plasma lipids are of some concern but of difficult interpretation.

Entities:  

Keywords:  Americas; Androgens; Anthropometry; Biology; Chile; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Control Groups; Cyproterone Acetate; Desogestrel; Developing Countries; Diseases; Endocrine System; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Follicle Stimulating Hormone; Gonadotropins; Gonadotropins, Pituitary; Hirsutism; Hormone Antagonists; Hormones; Laboratory Examinations And Diagnoses; Latin America; Lipid Metabolic Effects; Lipids; Luteinizing Hormone--analysis; Measurement; Oral Contraceptives; Oral Contraceptives, Low-dose; Physiology; Pituitary Hormones; Prolactin--analysis; Research Methodology; Signs And Symptoms; South America; Studies; Testosterone--analysis; Treatment

Mesh:

Substances:

Year:  1991        PMID: 1827074     DOI: 10.1016/s0015-0282(16)54291-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls.

Authors:  Erin Lanzo; Maria Monge; Maria Trent
Journal:  Pediatr Ann       Date:  2015-09       Impact factor: 1.132

Review 2.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.

Authors:  Richard S Legro; Silva A Arslanian; David A Ehrmann; Kathleen M Hoeger; M Hassan Murad; Renato Pasquali; Corrine K Welt
Journal:  J Clin Endocrinol Metab       Date:  2013-10-22       Impact factor: 5.958

4.  Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India.

Authors:  Duru Shah; Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun

5.  Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis.

Authors:  Lina S Silva-Bermudez; Freddy J K Toloza; Maria C Perez-Matos; Russell J de Souza; Laura Banfield; Andrea Vargas-Villanueva; Carlos O Mendivil
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

Review 6.  Cyproterone acetate for hirsutism.

Authors:  Z M Van der Spuy; P A le Roux
Journal:  Cochrane Database Syst Rev       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.